Q-omics provides the consensus-scored SLC45A4 profile across patient tissues and cancer cell-line models. SLC45A4 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SLC45A4 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, SLC45A4 RNA expression shows 20,363 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, THCA, and ACC as cancer lineages where SLC45A4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC45A4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC45A4 survival associations across molecular data types. SLC45A4 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC45A4 RNA expression–survival associations across cancer types. High SLC45A4 expression shows unfavorable associations in UVM, BRCA and COAD, but favorable associations in KIRC, HNSC and SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SLC45A4 RNA expression.
This table summarizes SLC45A4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SLC45A4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC45A4 shows lower tumor expression in THCA, KICH, KIRP and KIRC and higher tumor expression in LIHC and COAD. The THCA box plot shows higher SLC45A4 RNA expression in normal versus tumor tissue (log2 FC = −0.936, t-test p < 0.001).
This table shows molecular features associated with SLC45A4 in patient tissues and cancer cell lines. In patient samples, SLC45A4 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC45A4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Lymphoma.
